A heterodimeric antibody comprising: a) a first heavy chain comprising: i) a first variant Fc domain; and ii) a single chain Fv region (scFv), wherein said scFv region comprises a first variable heavy domain, a first variable light domain and a charged scFv linker, wherein said charged scFv linker covalently attaches said first variable heavy domain and said first variable light domain; b) a second heavy chain comprising a VH-CH1-hinge-CH2-CH3 monomer, wherein VH is a second variable heavy domain and CH2-CH3 is a second variant Fc domain; and c) a light chain comprising a second variable light domain and a light constant domain; wherein said CH1-hinge-CH2-CH3 of said second heavy chain comprises amino acid substitutions N208D/Q295E/N384D/Q418E/N421D, wherein said first and second variant Fc domains each comprise amino acid substitutions E233P/L234V/L235A/G236del/S267K, wherein said first variant Fc domain comprises amino acid substitutions S364K/E357Q and said second variant Fc domain comprises amino acid substitutions L368D/K370S, wherein said first variable heavy domain comprises SEQ ID NO: 1081 and said first variable light domain comprises SEQ ID NO: 1085, wherein said second variable heavy domain comprises SEQ ID NO: 1071 and said second variable light domain comprises SEQ ID NO: 1076, wherein numbering is according to the EU index as in Kabat. a) a first heavy chain comprising: i) a first variant Fc domain; and ii) a single chain Fv region (scFv), wherein said scFv region comprises a first variable heavy domain, a first variable light domain and a charged scFv linker, wherein said charged scFv linker covalently attaches said first variable heavy domain and said first variable light domain; i) a first variant Fc domain; and ii) a single chain Fv region (scFv), wherein said scFv region comprises a first variable heavy domain, a first variable light domain and a charged scFv linker, wherein said charged scFv linker covalently attaches said first variable heavy domain and said first variable light domain; b) a second heavy chain comprising a VH-CH1-hinge-CH2-CH3 monomer, wherein VH is a second variable heavy domain and CH2-CH3 is a second variant Fc domain; and c) a light chain comprising a second variable light domain and a light constant domain; wherein said CH1-hinge-CH2-CH3 of said second heavy chain comprises amino acid substitutions N208D/Q295E/N384D/Q418E/N421D, wherein said first and second variant Fc domains each comprise amino acid substitutions E233P/L234V/L235A/G236del/S267K, wherein said first variant Fc domain comprises amino acid substitutions S364K/E357Q and said second variant Fc domain comprises amino acid substitutions L368D/K370S, wherein said first variable heavy domain comprises SEQ ID NO: 1081 and said first variable light domain comprises SEQ ID NO: 1085, wherein said second variable heavy domain comprises SEQ ID NO: 1071 and said second variable light domain comprises SEQ ID NO: 1076, wherein numbering is according to the EU index as in Kabat. wherein said CH1-hinge-CH2-CH3 of said second heavy chain comprises amino acid substitutions N208D/Q295E/N384D/Q418E/N421D, wherein said first and second variant Fc domains each comprise amino acid substitutions E233P/L234V/L235A/G236del/S267K, wherein said first variant Fc domain comprises amino acid substitutions S364K/E357Q and said second variant Fc domain comprises amino acid substitutions L368D/K370S, wherein said first variable heavy domain comprises SEQ ID NO: 1081 and said first variable light domain comprises SEQ ID NO: 1085, wherein said second variable heavy domain comprises SEQ ID NO: 1071 and said second variable light domain comprises SEQ ID NO: 1076, wherein numbering is according to the EU index as in Kabat. <EOS>